Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016
Assets:
Total Expense for the Six Months Ended June 30, 2017	$ (725,044)		$ (39,951)		$ (929,006)	$ (169,576)
Disposal Group, Held-for-sale, Not Discontinued Operations | Somar
Assets:
Total Expense for the Six Months Ended June 30, 2017					(9,900)
U.S. Branded Pharmaceuticals
Assets:
Total Expense for the Six Months Ended June 30, 2017	(20,600)
U.S. Generic Pharmaceuticals
Assets:
Total Expense for the Six Months Ended June 30, 2017			$ (40,000)	$ (29,300)
U.S. Generic Pharmaceuticals | 2017 US Generic Pharmaceuticals Restructuring
Assets:
Total Expense for the Six Months Ended June 30, 2017	(57,500)
International Pharmaceuticals
Assets:
Total Expense for the Six Months Ended June 30, 2017		$ (82,600)
Certain property, plant and equipment | 2017 US Generic Pharmaceuticals Restructuring
Assets:
Total Expense for the Six Months Ended June 30, 2017					(32,000)
Fair value, measurements, nonrecurring
Assets:
Total Expense for the Six Months Ended June 30, 2017					(929,006)
Fair value, measurements, nonrecurring | Intangible assets | U.S. Branded Pharmaceuticals
Assets:
Total Expense for the Six Months Ended June 30, 2017					(52,096)
Fair value, measurements, nonrecurring | Intangible assets | U.S. Generic Pharmaceuticals
Assets:
Total Expense for the Six Months Ended June 30, 2017					(398,423)
Fair value, measurements, nonrecurring | Intangible assets | International Pharmaceuticals
Assets:
Total Expense for the Six Months Ended June 30, 2017					(145,359)
Fair value, measurements, nonrecurring | Goodwill | U.S. Branded Pharmaceuticals
Assets:
Total Expense for the Six Months Ended June 30, 2017					(180,430)
Fair value, measurements, nonrecurring | Goodwill | Paladin Canada reporting unit
Assets:
Total Expense for the Six Months Ended June 30, 2017					(82,602)
Fair value, measurements, nonrecurring | Goodwill | Somar reporting unit
Assets:
Total Expense for the Six Months Ended June 30, 2017					(25,712)
Fair value, measurements, nonrecurring | Certain property, plant and equipment
Assets:
Total Expense for the Six Months Ended June 30, 2017					(44,384)
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment	0				0
Total	0				0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring | U.S. Branded Pharmaceuticals
Assets:
Certain segment intangible assets	0				0
Goodwill	0				0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring | U.S. Generic Pharmaceuticals
Assets:
Certain segment intangible assets	0				0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring | International Pharmaceuticals
Assets:
Certain segment intangible assets	0				0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring | Paladin Canada reporting unit
Assets:
Goodwill	0				0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring | Somar reporting unit
Assets:
Goodwill	0				0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment	0				0
Total	0				0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring | U.S. Branded Pharmaceuticals
Assets:
Certain segment intangible assets	0				0
Goodwill	0				0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring | U.S. Generic Pharmaceuticals
Assets:
Certain segment intangible assets	0				0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring | International Pharmaceuticals
Assets:
Certain segment intangible assets	0				0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring | Paladin Canada reporting unit
Assets:
Goodwill	0				0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring | Somar reporting unit
Assets:
Goodwill	0				0
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment	0				0
Total	1,363,126				1,363,126
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring | U.S. Branded Pharmaceuticals
Assets:
Certain segment intangible assets	17,781				17,781
Goodwill	828,818				828,818
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring | U.S. Generic Pharmaceuticals
Assets:
Certain segment intangible assets	409,874				409,874
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring | International Pharmaceuticals
Assets:
Certain segment intangible assets	21,772				21,772
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring | Paladin Canada reporting unit
Assets:
Goodwill	84,881				84,881
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring | Somar reporting unit
Assets:
Goodwill	$ 0				$ 0